Imaging proliferation in vivo with [F-18] FLT and positron emission tomography
AF Shields, JR Grierson, BM Dohmen, H Machulla… - Nature medicine, 1998 - nature.com
AF Shields, JR Grierson, BM Dohmen, H Machulla, JC Stayanoff, JM Lawhorn-Crews…
Nature medicine, 1998•nature.comPositron emission tomography (PET) is now regularly used in the diagnosis and staging of
cancer. These uses and its ability to monitor treatment response would be aided by the
development of imaging agents that can be used to measure tissue and tumor proliferation.
We have developed and tested [F-18] FLT (3'-deoxy-3'-fluorothymidine); it is resistant to
degradation, is retained in proliferating tissues by the action of thymidine kinase 1 (TK), and
produces high-contrast images of normal marrow and tumors in canine and human subjects.
cancer. These uses and its ability to monitor treatment response would be aided by the
development of imaging agents that can be used to measure tissue and tumor proliferation.
We have developed and tested [F-18] FLT (3'-deoxy-3'-fluorothymidine); it is resistant to
degradation, is retained in proliferating tissues by the action of thymidine kinase 1 (TK), and
produces high-contrast images of normal marrow and tumors in canine and human subjects.
Abstract
Positron emission tomography (PET) is now regularly used in the diagnosis and staging of cancer. These uses and its ability to monitor treatment response would be aided by the development of imaging agents that can be used to measure tissue and tumor proliferation. We have developed and tested [F-18] FLT (3'-deoxy-3'-fluorothymidine); it is resistant to degradation, is retained in proliferating tissues by the action of thymidine kinase 1 (TK), and produces high-contrast images of normal marrow and tumors in canine and human subjects.
nature.com